Yunnan biological valley erigeron breviscapus pharmaceutical co., ltd.

Through continuous technical transformation, the company has formed an annual production capacity of 60 million small-volume injections,/kloc-0.00 million powder injections, 200 million capsules, 800 million tablets,/kloc-0.00 billion dripping pills, 55 million soft capsules and 200 tons of refined raw materials, including small-volume injections, tablets, capsules, anti-tumor injections, freeze-dried powder injections and freeze-dried powder injections. In 2004, it passed the ISO900 1:2000: 2000 quality management system certification, in 2005 it passed the ISO 1400 1 environmental management system certification, and in 2006 it passed the cleaner production site audit. Since its establishment, the company has achieved outstanding business performance, and its total industrial output value, sales revenue and total profits and taxes have been in the forefront of pharmaceutical enterprises in Yunnan Province for several consecutive years.

Bio-Valley Pharmaceutical is committed to the research, development and production of plant medicines. At present, it is the only enterprise in China that mainly produces Erigeron breviscapus (Erigeron breviscapus) series products. Approved by the state, the enterprise postdoctoral research center and the enterprise technology center recognized by the state have been established. The leading product "erigeron breviscapus injection" occupies more than 50% of the national erigeron breviscapus series drug market, and was successively rated as "Yunnan famous brand product" in 2003 and 2006. The newly marketed product "Dengzhanshengmai Capsule" is a compound oral preparation consisting of Erigeron breviscapus, ginseng, Ophiopogon japonicus and Schisandra chinensis. It is suitable for the treatment of cerebral infarction and cerebral hemorrhage in recovery period, and has good effect on reducing blood lipid and preventing secondary stroke. It has been listed in the national basic medical insurance and industrial injury insurance drug list and successfully registered in Malaysia. In 2007, it was included in the "2006BAI04A02 Project of the Eleventh Five-Year National Science and Technology Support Plan". This product will become a new economic pillar after Erigeron breviscapus injection. The new drug "Erigeron breviscapus dropping pills" is produced by micronization technology, which effectively improves the bioavailability and curative effect, and has been put on the market at present. "erigeron breviscapus injection" is a new product developed on the basis of "erigeron breviscapus injection", which has better stability and has entered the stage of production approval. Adhering to the business philosophy of "responsibility, cooperation and development", Bio-Valley Pharmaceutical has built a well-known brand of Bio-Valley with advanced scientific research, production, management and marketing, created a series of brand-name products of Erigeron breviscapus, provided products and services needed by customers, and made contributions to the development of national pharmaceutical industry and serving human health.